We have reported recently that mig-6 is a negative regulator of epidermal growth factor receptor (EGFR)-dependent skin morphogenesis and tumor formation in vivo. In the liver, ablation of mig-6 leads to an increase in EGFR protein levels, suggesting that mig-6 is a negative regulator of EGFR function. In line with this observation, primary hepatocytes isolated from mig-6 knockout and wild-type control mice display sustained mitogenic signaling in response to EGF. In Selleck MK-1775 order to explore the role of mig-6 in the liver in vivo, we

analyzed liver regeneration in mig-6 knockout and wild-type control mice. Interestingly, mig-6 knockout mice display enhanced hepatocyte proliferation in the initial phases after partial hepatectomy. This phenotype correlates with activation of endogenous EGFR signaling, predominantly through the protein kinase B pathway. In addition, mig-6 is an endogenous inhibitor of EGFR signaling and EGF-induced tumor cell migration in human liver cancer cell lines. Moreover, mig-6 is down-regulated in human hepatocellular carcinoma and this correlates BMS-777607 solubility dmso with increased EGFR expression. Conclusion: Our data implicate mig-6 as a regulator of EGFR activity in hepatocytes and as a suppressor of EGFR signaling in human liver cancer. (HEPATOLOGY 2009.) In rodents,

the liver has a tremendous capacity to regenerate. Normally, hepatocytes are in a quiescent state and rarely divide. In response to two-thirds partial hepatectomy (PH), however, 95% of all hepatocytes synchronously re-enter the cell cycle and restore the liver to its full size.1 This rapid growth provides an excellent model to study the molecular mechanisms of cell proliferation in vivo. Importantly, defects in liver regeneration can contribute to the development of severe diseases such as liver cirrhosis and

liver cancer.2 Teicoplanin The process of liver regeneration is dependent on various growth factors, cytokines, and metabolic processes. Cytokines, like tumor necrosis factor-α or interleukin-6, act as the priming factors of liver regeneration, driving quiescent hepatocytes into the cell cycle.3 Several growth factors and receptor tyrosine kinases control cell cycle progression by stimulating the S-phase entry of hepatocytes. The epidermal growth factor receptor (EGFR), heparin-binding EGF-like growth factor (HB-EGF), transforming growth factor-α (TGFα), amphiregulin, and the MET receptor have been described to be potent regulators of liver regeneration.4–8 Mitogen-inducible gene-6 (mig-6)—also known as RALT, gene33, or Errfi1—is an adaptor protein implicated in the regulation of receptor tyrosine kinases.9, 10 Mig-6 can be induced by a variety of external stimuli including growth factors, hypoxia, and stress.11 Overexpression or small interfering RNA (siRNA)-mediated knockdown studies have shown that mig-6 is a negative regulator of EGF receptor signaling.